Clinical Microbiology Newsletter
Volume 30, Issue 12 , Pages 87-95 , 15 June 2008

Clinical and Epidemiological Aspects of Clostridium difficile

  • Matthew T. Oughton, MD, FRCPC

      Affiliations

    • Faculty of Medicine, McGill University, SMBD-Jewish General Hospital, Montreal, Quebec, Canada
    • ,
  • Mark A. Miller, MD, FRCPC

      Affiliations

    • Faculty of Medicine, McGill University, SMBD-Jewish General Hospital, Montreal, Quebec, Canada
    • Division of Clinical Microbiology, Department of Medicine, SMBD-Jewish General Hospital, Montreal, Quebec, Canada
    • Division of Infectious Diseases, Department of Medicine, SMBD-Jewish General Hospital, Montreal, Quebec, Canada
    • Corresponding Author InformationMailing Address: Mark A. Miller, M.D., FRCPC, SMBD-Jewish General Hospital, 3755 Cote-Ste-Catherine Road, Suite G-139, Montreal, Quebec, Canada H3T 1E2. Tel: 514-340-8294. Fax: 514-340-7546

References 

  1. Archibald LK , Banerjee SN , Jarvis WR . Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001 . J. Infect. Dis. . 2004;189:1585–1589
  2. Ricciardi R , et al.   Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States . Arch. Surg. . 2007;142:624–631
  3. Redelings MD , Sorvillo F , Mascola L . Increase in Clostridium difficile-related mortality rates, United States, 1999-2004 . Emerg. Infect. Dis. . 2007;13:1417–1419
  4. Centers for Disease Control and Prevention  . Data and statistics about Clostridium difficile infections . http://www.cdc.gov/ncidod/dhqp/id_Cdiff_data.html 2007;
  5. McDonald LC , et al.   An epidemic, toxin gene-variant strain of Clostridium difficile . N. Engl. J. Med. . 2005;353:2433–2441
  6. Tan ET , et al.   Clostridium difficile-associated disease in New Jersey hospitals, 2000–2004 . Emerg. Infect. Dis. . 2007;13:498–500
  7. Kyne L , et al.   Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile . Clin. Infect. Dis. . 2002;34:346–353
  8. Chernak E , et al.   Severe Clostridium difficile-associated disease in populations previously at low risk — four states, 2005 . MMWR Morb. Mortal. Wkly. Rep. . 2005;54:1201–1205
  9. Miller MA , et al.   Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals . Infect. Contr. Hosp. Epidemiol. . 2002;23:137–140
  10. Eggertson L , Sibbald B . Hospitals battling outbreaks of C. difficile . CMAJ . 2004;171:19–21
  11. Weiss K , et al.   Clostridium difficile-associated diarrhoea rates and global antibiotic consumption in five Quebec institutions from 2001 to 2004 . Int. J. Antimicrob. Agents . 2007;30:309–314
  12. Loo VG , et al.   A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality . N. Engl. J. Med. . 2005;353:2442–2449
  13. Hubert B , et al.   A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec . Clin. Infect. Dis. . 2007;44:238–244
  14. Pepin J , et al.   Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity . CMAJ . 2004;171:466–472
  15. Pepin J , et al.   Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada . Clin. Infect. Dis. . 2005;40:1591–1597
  16. MacCannell DR , et al.   Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from eastern and western Canada . J. Clin. Microbiol. . 2006;44:2147–2152
  17. Canadian Nosocomial Infection Surveillance Program . Clostridium difficile associated disease (CDAD) surveillance: 2004-2005 . http://www.phac-aspc.gc.ca/nois-sinp/projects/cdad_e.html 2007;
  18. Kuijper EJ , Coignard B , Tull P . Emergence of Clostridium difficile-associated disease in North America and Europe . Clin. Microbiol. Infect. . 2006;12:2–18
  19. Kuijper EJ , et al.   Update of Clostridium difficile-associated disease due to PCR ribotype 027 in Europe . Euro Surveill. . 2007;12:E1–E2
  20. Lyytikäinen O., et al. 2007. First isolation of Clostridium difficile PCR ribotype 027 in Finland. Euro Surveill. E071108.2
  21. Bouvet, P. 2006. Personal communication, M. Oughton (Ed.). Montreal.
  22. Carlier JP . Catalogue data sheet of Clostridium difficile CIP 107932. 2007 . http://www.crbip.pasteur.fr/fiches/fichecata.jsp?crbip=107932 2003;
  23. Popoff MR , et al.   Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain . Infect. Immun. . 1988;56:2299–2306
  24. Mutlu E , et al.   Molecular characterization and antimicrobial susceptibility patterns of Clostridium difficile strains isolated from hospitals in south-east Scotland . J. Med. Microbiol. . 2007;56:921–929
  25. Wilcox MH , et al.   In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates . J. Antimicrob. Chemother. . 2000;46:551–556
  26. Goorhuis A , et al.   Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands . Clin. Infect. Dis. . 2007;45:695–703
  27. Alonso R , et al.   In vitro activity of new quinolones against Clostridium difficile . J. Antimicrob. Chemother. . 2001;47:195–197
  28. Pituch H , et al.   Toxin profiles and resistances to macrolides and newer fluoroquinolones as epidemicity determinants of clinical isolates of Clostridium difficile from Warsaw, Poland . J. Clin. Microbiol. . 2007;45:1607–1610
  29. Rupnik M , et al.   New types of toxin A-negative, toxin B-positive strains among Clostridium difficile isolates from Asia . J. Clin. Microbiol. . 2003;41:1118–1125
  30. Sawabe E , et al.   Molecular analysis of Clostridium difficile at a university teaching hospital in Japan: a shift in the predominant type over a five-year period . Eur. J. Clin. Microbiol. Infect. Dis. . 2007;26:695–703
  31. Kato, H. et al. 2007. First isolation of Clostridium difficile 027 in Japan. Euro Surveill. E070111.3
  32. Bidet P , et al.   Comparison of PCR-ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for typing Clostridium difficile . J. Clin. Microbiol. . 2000;38:2484–2487
  33. Clabots CR , et al.   Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems . J. Clin. Microbiol. . 1993;31:1870–1875
  34. Delmee M , et al.   Comparison of serogrouping and polyacrylamide gel electrophoresis for typing Clostridium difficile . J. Clin. Microbiol. . 1986;24:991–994
  35. Klaassen CHW , van Haren HA , Horrevorts AM . Molecular fingerprinting of Clostridium difficile isolates: pulsed-field gel electrophoresis versus amplified fragment length polymorphism . J. Clin. Microbiol. . 2002;40:101–104
  36. Kristjansson M , et al.   Comparison of restriction endonuclease analysis, ribotyping, and pulsed-field gel electrophoresis for molecular differentiation of Clostridium difficile strains . J. Clin. Microbiol. . 1994;32:1963–1969
  37. O'Neill GL , et al.   A comparison of PCR ribotyping and pyrolysis mass spectrometry for typing clinical isolates of Clostridium difficile . Anaerobe . 1996;2:211–215
  38. Poilane I , et al.   Molecular characterization of Clostridium difficile clinical isolates in a geriatric hospital . J. Med. Microbiol. . 2007;56:386–390
  39. Wust J , et al.   Investigation of an outbreak of antibiotic-associated colitis by various typing methods . J. Clin. Microbiol. . 1982;16:1096–1101
  40. Brazier JS , et al.   Preliminary findings of the international typing study on Clostridium difficile . Clin. Infect. Dis. . 1997;25(Suppl. 2):S199–S201
  41. Brazier JS . Typing of Clostridium difficile . Clin. Microbiol. Infect. . 2001;7:428–431
  42. Nakamura S , et al.   Isolation of Clostridium difficile from feces and the antibody in sera of young and elderly adults . Microbiol. Immunol. . 1981;25:345–351
  43. Sell TL , Schaberg DR , Fekety FR . Bacteriophage and bacteriocin typing scheme for Clostridium difficile . J. Clin. Microbiol. . 1983;17:1148–1152
  44. Tabaqchali S , et al.   Typing scheme for Clostridium difficile: its application in clinical and epidemiological studies . Lancet . 1984;323:935–938
  45. Spigaglia P , et al.   Molecular typing and long-term comparison of Clostridium difficile strains by pulsed-field gel electrophoresis and PCR-ribotyping . J. Med. Microbiol. . 2001;50:407–414
  46. Gürtler V . Typing of Clostridium difficile strains by PCR amplification of variable length 16S-23S rDNA spacer regions . J. Gen. Microbiol. . 1993;139:3089–3097
  47. O'Neill GL , et al.   Modification of a PCR ribotyping method for application as a routine typing scheme for Clostridium difficile . Anaerobe . 1996;2:205–209
  48. Marsh JW , et al.   Multilocus variable-number tandem-repeat analysis for investigation of Clostridium difficile transmission in hospitals . J. Clin. Microbiol. . 2006;44:2558–2566
  49. Rupnik M , et al.   A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates . J. Clin. Microbiol. . 1998;36:2240–2247
  50. Rupnik M , et al.   Comparison of toxinotyping and PCR ribotyping of Clostridium difficile strains and description of novel toxinotypes . Microbiology . 2001;147:439–447
  51. Sebaihia M , et al.   The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome . Nat. Genet. . 2006;38:779–786
  52. Forgetta V. et al. 2007. Developing genome resources for Clostridium difficile. In 2020 vision: adaptation to environmental change (Genome Canada International Conference, 2007). Genome Canada, Quebec City, Quebec, Canada.
  53. Maiden MCJ , et al.   Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms . Proc. Natl. Acad. Sci. USA . 1998;95:3140–3145
  54. Lemee L , et al.   Multilocus sequence typing analysis of human and animal Clostridium difficile iso-lates of various toxigenic types . J. Clin. Microbiol. . 2004;42:2609–2617
  55. Lemee L , et al.   Multilocus sequence analysis and comparative evolution of virulence-associated genes and housekeeping genes of Clostridium difficile . Microbiology . 2005;151:3171–3180
  56. van den Berg RJ , et al.   Typing and subtyping of Clostridium difficile isolates by using multiple-locus variable-number tandem-repeat analysis . J. Clin. Microbiol. . 2007;45:1024–1028
  57. Delmee M , et al.   Laboratory diagnosis of Clostridium difficile-associated diarrhoea: a plea for culture . J. Med. Microbiol. . 2005;54:187–191
  58. Reller ME , et al.   Yield of stool culture with isolate toxin testing versus a two-step algorithm including stool toxin testing for detection of toxigenic Clostridium difficile . J. Clin. Microbiol. . 2007;45:3601–3605
  59. Bouza E , et al.   “Second-look” cytotoxicity: an evaluation of culture plus cytotoxin assay of Clostridium difficile isolates in the laboratory diagnosis of CDAD . J. Hosp. Infect. . 2001;48:233–237
  60. Borriello SP , et al.   Molecular, immunological, and biological characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile . Infect. Immun. . 1992;60:4192–4199
  61. Rupnik M . How to detect Clostridium difficile variant strains in a routine laboratory . Clin. Microbiol. Infect. . 2001;7:417–420
  62. Alfa MJ , et al.   Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea . J. Clin. Microbiol. . 2000;38:2706–2714
  63. Kato H , et al.   Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR . J. Clin. Microbiol. . 1998;36:2178–2182
  64. Sambol SP , et al.   Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease . Infect. Immun. . 2000;68:5480–5487
  65. Blake JE , Mitsikosta F , Metcalfe MA . Immunological detection and cytotoxic properties of toxins from toxin A-positive, toxin B-positive Clostridium difficile variants . J. Med. Microbiol. . 2004;53:197–205
  66. Barbut F , et al.   A European survey of diagnostic methods and testing protocols for Clostridium difficile . Clin. Microbiol. Infect. . 2003;9:989–996
  67. Robert Michael Educational Institute. 2007. Clostridium difficile-associated disease: a focus on clinical presentation and diagnosis. CME Newslett. 1:Sept. Available online at http://www.rmei.com/CDAD509/.
  68. Wilkins TD , Lyerly DM . Clostridium difficile testing: after 20 years, still challenging . J. Clin. Microbiol. . 2003;41:531–534
  69. Musher DM , et al.   Detection of Clostridium difficile toxin: comparison of enzyme immunoassay results with results obtained by cytotoxicity assay . J. Clin. Microbiol. . 2007;45:2737–2739
  70. Turgeon DK , et al.   Six rapid tests for direct detection of Clostridium difficile and its toxins in fecal samples compared with the fibroblast cytotoxicity assay . J. Clin. Microbiol. . 2003;41:667–670
  71. Belanger SD , et al.   Rapid detection of Clostridium difficile in feces by real-time PCR . J. Clin. Microbiol. . 2003;41:730–734
  72. van den Berg RJ , et al.   Evaluation of real-time PCR and conventional diagnostic methods for the detection of Clostridium difficile-associated diarrhoea in a prospective multicentre study . J. Med. Microbiol. . 2007;56:36–42
  73. Peterson LR , et al.   Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea . Clin. Infect. Dis. . 2007;45:1152–1160
  74. Fekety R . Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis . Am. J. Gastroenterol. . 1997;92:739–750
  75. Boyce JM , Pittet D . Guideline for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force . Infect. Contr. Hosp. Epidemiol. . 2002;23:S3–S40
  76. King S . Provision of alcohol hand rub at the hospital bedside: a case study . J. Hosp. Infect. . 2004;56(Suppl. 2):10–12
  77. Oughton, M. et al. 2007. Alcohol rub and antiseptic wipes are inferior to soap and water for removal of Clostridium difficile by handwashing, abstr. no. K-1376a. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, 17-20 September, 2007. American Society for Microbiology, Washington, DC.
  78. Boyce JM , et al.   Lack of association between the increased incidence of Clostridium difficile-associated disease and the increasing use of alcohol-based hand rubs . Infect. Contr. Hosp. Epidemiol. . 2006;27:479–483
  79. Dendukuri N , et al.   Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review . CMAJ . 2005;173:167–170
  80. Sougioultzis S , et al.   Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea . Gastroenterology . 2005;128:764–770
  81. Anonymous  . American Society of Hospital Pharmacists' therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease . Am. J. Health Syst. Pharm. . 1998;55:1407–1411
  82. Wenisch C , et al.   Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea . Clin. Infect. Dis. . 1996;23:813–818
  83. Teasley DG , et al.   Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis . Lancet . 1983;322:1043–1046
  84. Belmares J , et al.   Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system . J. Infect. . 2007;55:495–501
  85. Zar FA , et al.   A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity . Clin. Infect. Dis. . 2007;45:302–307
  86. Louie, T. et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea (CDAD), abstr. no. K-425a. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, 17-20 September, 2007. American Society for Microbiology, Washington, DC.
  87. Bolton RP , Culshaw MA . Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile . Gut . 1986;27:1169–1172
  88. Keighley MR , et al.   Random-ised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea . Br. Med. J. . 1978;2:1667–1669
  89. Apisarnthanarak A , Razavi B , Mundy LM . Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature . Clin. Infect. Dis. . 2002;35:690–696
  90. Surowiec D , et al.   Past, present, and future therapies for Clostridium difficile-associated disease . Ann. Pharmacother . 2006;40:2155–2163
  91. Shetler K , et al.   Decompressive colonoscopy with intracolonic vancomycin administration for the treatment of severe pseudomembranous colitis . Surg. Endosc. . 2001;15:653–659
  92. Nelson, R. 2007. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst. Rev. Issue 3, Article no. CD004610. DOI:10.1002/14651858.CD004610.pub3.
  93. Berenbaum PL . Oral rifaximin in treatment of Clostridium difficile-associated diarrhea . Am. J. Gastroenterol. . 2006;101:S199
  94. Johnson S , et al.   Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin . Clin. Infect. Dis. . 2007;44:846–848
  95. Galang M.A., et al. 2007. Rifampin susceptibility by agar dilution and Etest predicts susceptibility to rifaximin in Clostridium difficile, abstr. no. K-425. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, 17-20 September, 2007. American Society for Microbiology, Washington, D.C.
  96. DuPont HL , et al.   A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea . Ann. Intern. Med. . 2005;142:805–812
  97. Musher DM , et al.   Nitazoxanide for the treatment of Clostridium difficile Colitis . Clin. Infect. Dis. . 2006;43:421–427
  98. Young JD , et al.   Nitazoxanide versus metronidazole for Clostridium difficile-associated colitis . Clin. Infect. Dis. . 2007;44:152
  99. Farver DK , Hedge DD , Lee SC . Ramoplanin: a lipoglycodepsipeptide antibiotic . Ann. Pharmacother. . 2005;39:863–868
  100. Leach, T., J. Pullman, and J. Prieto. 2004. Ramoplanin vs. vancomycin in the treatment of Clostridium difficile diarrhea: a phase 2 study, abstr. no. K-985a. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother., Washington, DC., 30 October to 4 November, 2004. American Society for Microbiology, Washington, DC.
  101. Ackermann G , et al.   In vitro activity of OPT-80 against Clostridium difficile . Antimicrob. Agents Chemother. . 2004;48:2280–2282
  102. Louie, T. et al. 2005. Safety, pharmacokinetics and outcomes of PAR-101 in healthy subjects and patients with Clostridium difficile-associated diarrhea (CDAD), abstr. no. LB2-29. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., Washington, DC., 16-19 December, 2005. American Society for Microbiology, Washington, DC.
  103. Jodlowski TZ , et al.   Emerging therapies in the treatment of Clostridium difficile-associated disease . Ann Pharmacother. . 2006;40:2164–2169
  104. McPherson S , et al.   Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea . Dis. Colon Rectum . 2006;49:640–645
  105. Wilcox MH . Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea . J. Antimicrob. Chemother. . 2004;53:882–884
  106. McFarland LV , et al.   A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease . JAMA . 1994;271:1913–1918
  107. McFarland LV . Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease . Am. J. Gastroenterol. . 2006;10:812–822
  108. Dendukuri N , Brophy J . Inappropriate use of meta-analysis to estimate efficacy of probiotics . Am. J. Gastroenterol. . 2007;102:201
  109. Hickson M , et al.   Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial . BMJ . 2007;335:80
  110. Wilcox MH , Sandoe JA . Results of study of probiotic yoghurt drink to prevent antibiotic-associated diarrhoea are not widely applicable . Br. Med. J. . 2007;335:171; (Letter.)
  111. Schwan A , et al.   Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces . Scand. J. Infect. Dis. . 1984;16:211–215
  112. Wettstein, A.R. et al. 2007. Fecal bacteriotherapy — an effective treatment for relapsing symptomatic Clostridium difficile infection, abstr. no. G-67. Abstr. 15th United European Gastroenterology Week (UEGW) 2007, United European Gastroenterology Federation, Paris, France.
  113. Aas J , Gessert CE , Bakken JS . Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube . Clin. Infect. Dis. . 2003;36:580–585
  114. Tvede M , Rask-Madsen J . Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients . Lancet . 1989;333:1156–1160
  115. Koss K , et al.   The outcome of surgery in fulminant Clostridium difficile colitis . Colorectal Dis. . 2006;8:149–154
  116. Haeck, O. et al. 2005. Risk factors for mortality among patients with severe Clostridium difficile-associated diarrhea (CDAD) in two tertiary care hospitals in Quebec (2003–2004), abstr. No. K1267. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., Washington, DC. 16-19 December, 2005. American Society for Microbiology, Washington, DC.

PII: S0196-4399(08)00028-7

doi: 10.1016/j.clinmicnews.2008.05.004

Clinical Microbiology Newsletter
Volume 30, Issue 12 , Pages 87-95 , 15 June 2008

Article Tools